Most Read Articles
27 Nov 2017
The amino sulphonic acid taurine may safely and effectively reduce portal pressure in cirrhotic patients, a study has shown.
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Rachel Soon, 3 days ago

Pharmaceutical industry representatives highlighted lesser-known career opportunities for licensed pharmacists at the recent Pharmaceutical Industries Pharmacists Insights 3.0 (PIPI 3.0) symposium in Petaling Jaya.

PPI effectively attenuates acid-related dyspepsia

29 Jun 2019

Monotherapy with a proton pump inhibitor appears to be effective in the treatment of functional dyspepsia (FD) symptoms associated with gastro-oesophageal reflux disease (GERD), according to a study.

The study included 233 patients (mean age, 56.5 years; 58 percent male; mean body mass index, 23.7 kg/m2) with FD and GERD, among whom 40 had mild, 151 had moderate and 42 had severe GERD symptoms. All patients were given PPI treatment for 4 weeks after endoscopy, and the severity of the symptoms and responses to treatment were evaluated prior to and after 4 weeks of treatment using the Gastroesophageal Reflux and Dyspepsia Therapeutic Efficacy and Satisfaction Test (GERD-TEST).

In the entire population, the pretreatment scores for the symptoms recorded were as follows: 3.7 for GERD-symptom subscale (SS), 3.3 for FD-SS, 3.6 for FD-epigastric pain syndrome symptom, and 3.0 for FD-postprandial distress-SS.

Analysis of the pretreatment scores for each symptom showed that a higher GERD-SS score was significantly associated with higher scores on any kind of FD score.

Furthermore, 4 weeks of PPI treatment led to a significant reduction in any of GERD/FD symptoms. Changes in the score for each symptom were markedly greater in the group of patients with more severe GERD-SS.

In light of the present data, PPI monotherapy may be considered the treatment of choice in patients with FD and more severe GERD symptom, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
27 Nov 2017
The amino sulphonic acid taurine may safely and effectively reduce portal pressure in cirrhotic patients, a study has shown.
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Rachel Soon, 3 days ago

Pharmaceutical industry representatives highlighted lesser-known career opportunities for licensed pharmacists at the recent Pharmaceutical Industries Pharmacists Insights 3.0 (PIPI 3.0) symposium in Petaling Jaya.